Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Turoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms guardian TM 7
- Sponsors Novo Nordisk
- 01 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 17 Feb 2017 Planned End Date changed from 1 Dec 2018 to 14 Dec 2018.
- 17 Feb 2017 Planned primary completion date changed from 1 Dec 2018 to 14 Dec 2018.